TWI800567B - 包含血漿激肽釋放酶抑制劑之劑型 - Google Patents
包含血漿激肽釋放酶抑制劑之劑型 Download PDFInfo
- Publication number
- TWI800567B TWI800567B TW107142516A TW107142516A TWI800567B TW I800567 B TWI800567 B TW I800567B TW 107142516 A TW107142516 A TW 107142516A TW 107142516 A TW107142516 A TW 107142516A TW I800567 B TWI800567 B TW I800567B
- Authority
- TW
- Taiwan
- Prior art keywords
- dosage forms
- plasma kallikrein
- kallikrein inhibitor
- inhibitor
- plasma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592242P | 2017-11-29 | 2017-11-29 | |
US62/592,242 | 2017-11-29 | ||
??1721515.3 | 2017-12-21 | ||
GB1721515.3 | 2017-12-21 | ||
GBGB1721515.3A GB201721515D0 (en) | 2017-12-21 | 2017-12-21 | Dosage forms comprising a plasma kallikrein inhibtor |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201924682A TW201924682A (zh) | 2019-07-01 |
TWI800567B true TWI800567B (zh) | 2023-05-01 |
Family
ID=61131610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107142516A TWI800567B (zh) | 2017-11-29 | 2018-11-28 | 包含血漿激肽釋放酶抑制劑之劑型 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3716952B1 (zh) |
KR (1) | KR20200093553A (zh) |
CN (1) | CN111432803B (zh) |
AU (1) | AU2018376817B2 (zh) |
BR (1) | BR112020010154A2 (zh) |
CA (1) | CA3083856A1 (zh) |
GB (1) | GB201721515D0 (zh) |
MA (1) | MA51204B1 (zh) |
TW (1) | TWI800567B (zh) |
WO (1) | WO2019106361A1 (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
GB201910125D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
CN115210230A (zh) * | 2020-03-04 | 2022-10-18 | 南京明德新药研发有限公司 | 杂环类化合物 |
CN112089710B (zh) * | 2020-08-07 | 2022-04-01 | 郑州大学 | 4-羟基异亮氨酸在制备抗肿瘤药物中的应用 |
WO2022079446A1 (en) * | 2020-10-15 | 2022-04-21 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
EP4232031A1 (en) | 2020-10-23 | 2023-08-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
EP4291186A1 (en) * | 2021-02-09 | 2023-12-20 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
EP4288036A1 (en) | 2022-04-27 | 2023-12-13 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
WO2024112719A1 (en) * | 2022-11-22 | 2024-05-30 | Rezolute, Inc. | Solid dosage forms of a plasma kallikrein inhibitor |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201625548A (zh) * | 2014-11-27 | 2016-07-16 | 卡爾維斯塔製藥有限公司 | 酶抑制劑 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
MX366498B (es) * | 2013-08-14 | 2019-07-11 | Kalvista Pharmaceuticals Ltd | Inhibidores de calicreina plasmatica. |
EA036251B1 (ru) * | 2014-03-07 | 2020-10-20 | Байокрист Фармасьютикалз, Инк. | Ингибиторы калликреина плазмы человека |
GB201421085D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421088D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
-
2017
- 2017-12-21 GB GBGB1721515.3A patent/GB201721515D0/en not_active Ceased
-
2018
- 2018-11-28 EP EP18815293.8A patent/EP3716952B1/en active Active
- 2018-11-28 AU AU2018376817A patent/AU2018376817B2/en active Active
- 2018-11-28 CA CA3083856A patent/CA3083856A1/en active Pending
- 2018-11-28 WO PCT/GB2018/053443 patent/WO2019106361A1/en active Search and Examination
- 2018-11-28 KR KR1020207015189A patent/KR20200093553A/ko not_active Application Discontinuation
- 2018-11-28 TW TW107142516A patent/TWI800567B/zh active
- 2018-11-28 CN CN201880077253.5A patent/CN111432803B/zh active Active
- 2018-11-28 BR BR112020010154-0A patent/BR112020010154A2/pt unknown
- 2018-11-28 MA MA51204A patent/MA51204B1/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201625548A (zh) * | 2014-11-27 | 2016-07-16 | 卡爾維斯塔製藥有限公司 | 酶抑制劑 |
Also Published As
Publication number | Publication date |
---|---|
CN111432803A (zh) | 2020-07-17 |
TW201924682A (zh) | 2019-07-01 |
MA51204A (fr) | 2020-10-07 |
KR20200093553A (ko) | 2020-08-05 |
AU2018376817A1 (en) | 2020-06-04 |
BR112020010154A2 (pt) | 2020-11-10 |
CN111432803B (zh) | 2022-08-26 |
EP3716952B1 (en) | 2022-01-05 |
MA51204B1 (fr) | 2022-02-28 |
GB201721515D0 (en) | 2018-02-07 |
AU2018376817B2 (en) | 2024-02-15 |
EP3716952A1 (en) | 2020-10-07 |
CA3083856A1 (en) | 2019-06-06 |
WO2019106361A1 (en) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI800567B (zh) | 包含血漿激肽釋放酶抑制劑之劑型 | |
IL274555A (en) | Solid forms of the plasma inhibitor kallikrein and their salts | |
EP3113772A4 (en) | Human plasma kallikrein inhibitors | |
GB201905265D0 (en) | Inflammasome inhibition | |
IL274558A (en) | Solid forms of the plasma inhibitor kallikrein and their salts | |
EP3246317A4 (en) | Btk inhibitor | |
EP3248980A4 (en) | Jak inhibitor | |
EP3447058A4 (en) | NEW WIDE SPECTRUM LACTAMASE INHIBITOR | |
IL291268A (en) | Human plasma kallikrein inhibitors | |
IL289764A (en) | Plasma kallikrein inhibitors | |
EP3342765A4 (en) | CATHEPSIN K INHIBITOR AND APPLICATION THEREOF | |
EP3705471A4 (en) | DOUBLE-HEADED PROTEASE INHIBITOR | |
EP3799535A4 (en) | PLASMA PROCESSOR | |
EP3814324A4 (en) | CATHEPSIN-C HEMMER | |
EP3532057A4 (en) | PRODRUGS OF KALLIKREINHEMMER | |
ZA202003899B (en) | Dosage forms comprising a plasma kallikrein inhibitor | |
EP3350448A4 (en) | INTERMEDIATE DISCHARGE PORT FOR A COMPRESSOR | |
GB201905620D0 (en) | Plasma etcher | |
EP4019048A4 (en) | ABCC11 INHIBITOR | |
EP3559357A4 (en) | EVACUATION SYSTEM | |
EP3463374A4 (en) | PROLONGED-ACTION PHARMACEUTICAL COMPOSITION BASED ON A PROTEASE INHIBITOR |